Nabriva Therapeutics plc provided revenue guidance for the fourth quarter of 2021. For the period, The company anticipates reporting that total revenue to grow at a mid-to-high single digit percentage as compare to third quarter of 2021's reported total revenue of $8.9 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
2023 | Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 | CI |
2023 | Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 3 | |
+15.19% | 121B | |
+19.91% | 114B | |
-19.80% | 20.43B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B | |
+119.39% | 10.96B |
- Stock Market
- Equities
- NBRVF Stock
- News Nabriva Therapeutics plc
- Nabriva Therapeutics plc Provides revenue Guidance for the Fourth Quarter of 2021